65th ASH Annual Meeting & Exposition: 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Screening to Vaccines

Symposia: MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological Oral and Poster Abstracts
Oral

Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)

Moderators:

Andrew R. Branagan, MD, Massachusetts General Hospital Cancer Center and Sigrun Thorsteinsdottir, MD, PhD,

Disclosures:

Branagan: Adaptive: Membership on an entity's Board of Directors or advisory committees; BeiGene: Membership on an entity's Board of Directors or advisory committees; CSL Behring: Membership on an entity's Board of Directors or advisory committees; Genzyme: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees.

2:00 PM

211

Quantitative MYD88 L265P Analysis Represents a Powerful Tool for Assessing Disease Response and Evaluating Clinical Trial Performance in Waldenstrom’s Macroglobulinemia

Nickolas Tsakmaklis, BA¹^*, Zachary R Hunter, PhD¹, Xia Liu, MD¹^*, Amanda Kofides¹^*, Shirong Liu, MD, PhD¹^*, Alexa G Canning, BA¹^*, Kris Richardson, PhD¹^*, Maria Luisa Guerrera, MD¹, Christopher J Patterson¹^*, Kirsten Meid, MPH¹^*, Timothy P. White¹^*, Megan Little¹^*, Katherine Stockman¹^*, Joshua Gustine, MD, MPH¹^*, Catherine A. Flynn, NP¹^*, Andrew R. Branagan, MD², Shayna R Sarosiek¹, Jorge J. Castillo, MD¹ and Steven P. Treon, MD, PhD, FRCP¹

¹Dana-Farber Cancer Institute, Bing Center for Waldenström Macroglobulinemia, Boston, MA
²Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA

2:15 PM

212

Early Intervention and Favorable Biologic Effects of Personalized Neoantigen Vaccines on the Tumor Immune Microenvironment in Smoldering Waldenstrom Macroglobulinemia

Szymon Szymura¹^*, Soungchul Cha²^*, Lin Wang³^*, Tiantian Zhang, PhD, MD¹^*, Zhenyuan Dong, PhD²^*, Aaron Anderson¹^*, Elizabeth Oh¹^*, Zhe Wang¹^*, Vincent Lee⁴^*, Sapna Parshottham⁵^*, Sheetal Rao⁶^*, Jasper B Olsem⁵^*, Brandon N Crumpton⁵^*, Hans Lee, MD⁷, Elisabet E. Manasanch, MD⁸^*, Sattva S. Neelapu, MD⁹, Sheeba K. Thomas, MD⁸ and Larry W. Kwak¹⁰

¹City of Hope, Duarte, CA
²City of Hope, Duarte
³city of hope, Duate
⁴city of hope, Duarte, CA
⁵MD Anderson Cancer Center, Houston
⁶UT- MD Anderson Cancer Center, Houston, TX
⁷Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX
⁸Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
⁹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
¹⁰Stephenson Lymphoma Center, Beckman Institute of the City of Hope, Duarte, CA

2:30 PM

213

Prospective Study of Acalabrutinib with Rituximab in Patients with Symptomatic Anti-MAG Mediated IgM Peripheral Neuropathy

Shayna R Sarosiek¹, Andrew R. Branagan, MD², Christopher Doughty³^*, Catherine A. Flynn, NP¹^*, Megan Little¹^*, Katherine Stockman¹^*, Timothy P. White¹^*, Kirsten Meid, MPH¹^*, Steven P. Treon, MD, PhD, FRCP¹ and Jorge J. Castillo, MD¹

¹Dana-Farber Cancer Institute, Bing Center for Waldenström Macroglobulinemia, Boston, MA
²Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA
³Department of Neurology, Brigham & Women's Hospital, Boston, MA

2:45 PM

214

The Early Benefits and Psychological Effects of Screening for Monoclonal Gammopathy of Undetermined Significance: Results of the Istopmm Study

Sæmundur Rögnvaldsson, MD, PhD^1,2^*, Sigrun Thorsteinsdottir, MD, PhD^2,3, Jon Oskarsson, MSc²^*, Elias Eythorsson, MD, PhD^1,2^*, Gudrun Asta Sigurdardottir²^*, Brynjar Vidarsson, MD¹^*, Pall T. Onundarson, MD^1,2, Bjarni Agnarsson, MD^1,2^*, Margret Sigurdardottir, MD¹^*, Isleifur Olafsson, MD, PhD¹^*, Ingunn Thorsteinsdottir, MD, PhD¹^*, Andri Steinthor Bjornsson, PhD⁴^*, Inga Dröfn Wessman, MSc⁴^*, Gauti Gislason, MSc²^*, Jon Kristinn Sigurdsson²^*, Andri Olafsson²^*, Ingigerdur Sverrisdottir, MD^2,5^*, Thorir E. Long, MD, PhD^2,6^*, Robert Palmason, MD^6,7^*, Signy Vala Sveinsdottir, MD, PhD¹^*, Fridbjorn Sigurdsson, MD⁸^*, Asdis Rosa Thordardottir²^*, Asbjorn Jonsson, MD⁸^*, Runolfur Palsson, MD^1,2^*, Olafur Indridason, MD, MHS¹^*, Elin Ruth Reed²^*, Gudlaug Katrin Hakonardottir, MSc²^*, Hlif Steingrimsdottir, MD¹^*, Malin Hultcrantz, MD, PhD⁹, Brian GM Durie, MD¹⁰, Stephen J. Harding, PhD¹¹, Thor Aspelund, PhD²^*, Ola Landgren, MD¹², Thorvardur Jon Love, MD, PhD^1,2^* and Sigurdur Y. Kristinsson, MD, PhD^1,2

¹Landspitali, The National University Hospital of Iceland, Reykjavik, Iceland
²Faculty of Medicine, University of Iceland, Reykjavik, Iceland
³Department of Hematology, Rigshospitalet, København, Copenhagen, Denmark
⁴Faculty of Psychology, University of Iceland, Reykjavik, Iceland
⁵Dept. of Haematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden
⁶Skane University Hospital, Lund, Sweden
⁷Faculty of Medicine, University of Iceland, Lund, AL, Sweden
⁸Akureyri Hospital, Akureyri, Iceland
⁹Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁰Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA
¹¹The Binding Site Inc., Birmingham, United Kingdom
¹²Sylvester Comprehensive Cancer Center, Myeloma Division, University of Miami, Miami, FL

3:00 PM

215

Clinical Utility of Monoclonal Gammopathy Screening in the Evaluation of Anemia

Mackenzie Maberry, MD^*, Caleb Smith, MD and Ronald S. Go, MD

Mayo Clinic, Rochester, MN

3:15 PM

216

Monoclonal Gammopathy of Undetermined Significance and the Risk of Thrombotic Events: Results from Istopmm, a Population-Based Screening Study in Iceland

Sæmundur Rögnvaldsson, MD, PhD^1,2^*, Alessandro Gasparini, PhD³^*, Sigrun Thorsteinsdottir, MD, PhD^2,4, Ingigerdur Sverrisdottir, MD^2,5^*, Elias Eythorsson, MD, PhD^1,2^*, Thorir E. Long, MD, PhD^2,6^*, Brynjar Vidarsson, MD¹^*, Pall T. Onundarson, MD^1,2, Bjarni Agnarsson, MD^1,2^*, Margret Sigurdardottir, MD¹^*, Isleifur Olafsson, MD, PhD¹^*, Ingunn Thorsteinsdottir, MD, PhD¹^*, Jon Oskarsson, MSc²^*, Robert Palmason, MD^6,7^*, Signy Vala Sveinsdottir, MD, PhD¹^*, Asdis Rosa Thordardottir²^*, Asbjorn Jonsson, MD⁸^*, Runolfur Palsson, MD^1,2^*, Olafur Indridason, MD, MHS¹^*, Thor Aspelund, PhD²^*, Gauti Gislason, MSc²^*, Andri Olafsson²^*, Jon Kristinn Sigurdsson²^*, Malin Hultcrantz, MD, PhD^9,10, Brian GM Durie, MD^11,12, Stephen J. Harding, PhD¹³, Ola Landgren, MD¹⁴, Thorvardur Jon Love, MD, PhD^1,2^* and Sigurdur Y. Kristinsson, MD, PhD^1,2

¹Landspitali, The National University Hospital of Iceland, Reykjavik, Iceland
²Faculty of Medicine, University of Iceland, Reykjavik, Iceland
³Red Door Analytics, Stockholm, Sweden
⁴Department of Hematology, Rigshospitalet, København, Copenhagen, Denmark
⁵Dept. of Haematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden
⁶Skane University Hospital, Lund, Sweden
⁷Faculty of Medicine, University of Iceland, Lund, AL, Sweden
⁸Akureyri Hospital, Akureyri, Iceland
⁹Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁰Department of Medicine, Weill Cornell Medical College, New York, NY
¹¹International Myeloma Foundation, Studio City, CA
¹²Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA
¹³The Binding Site Inc., Birmingham, United Kingdom
¹⁴Sylvester Comprehensive Cancer Center, Myeloma Division, University of Miami, Miami, FL

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

654.O2.6 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Screening to Vaccines–The Spectrum of Plasma Cell Disorders